GCM
CSTL icon

Graham Capital Management’s Castle Biosciences CSTL Stock Holding History

Graham Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$273K Buy
11,133
+205
+2% +$6.71K 0.01% 852
2025
Q4 		$425K Sell
10,928
-10,205
-48% -$329K 0.01% 694
2025
Q3 		$481K Sell
21,133
-20,650
-49% -$419K 0.01% 628
2025
Q2 		$853K Sell
41,783
-26,602
-39% -$492K 0.01% 632
2025
Q1 		$1.37M Buy
68,385
+26,709
+64% +$661K 0.02% 454
2024
Q4 		$1.11M Buy
41,676
+26,000
+166% +$792K 0.02% 466
2024
Q3 		$447K Buy
15,676
+824
+6% +$21K 0.01% 666
2024
Q2 		$323K Buy
14,852
+2,662
+22% +$59.3K 0.01% 706
2024
Q1 		$270K Sell
12,190
-2,690
-18% -$58.5K 0.01% 823
2023
Q4 		$321K Buy
+14,880
New +$262K 0.01% 708
2023
Q2 		– Sell
-31,011
Closed -$705K – 1015
2023
Q1 		$705K Buy
31,011
+4,076
+15% +$99.6K 0.02% 635
2022
Q4 		$634K Sell
26,935
-17,862
-40% -$414K 0.02% 689
2022
Q3 		$1.17M Sell
44,797
-28,875
-39% -$809K 0.05% 420
2022
Q2 		$1.62M Buy
+73,672
New +$1.71M 0.07% 279

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's CSTL Position: Q1 2026 in Review

Graham Capital Management increased its Castle Biosciences (CSTL) stake by 1.9% in Q1 2026, buying an estimated $6.71K and bringing the position to 11,133 shares worth $273K. The position accounts for 0.01% of the portfolio, ranked #852.

Graham Capital Management first reported a position in CSTL in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.62M in Q2 2022. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Graham Capital Management held 11,133 shares of Castle Biosciences worth $273K as of Q1 2026.
  • Graham Capital Management bought 205 Castle Biosciences shares in Q1 2026, an estimated $6.71K.
  • Castle Biosciences made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #852 holding.
  • Graham Capital Management first reported a position in Castle Biosciences in Q2 2022 and has held it in 14 quarters since.
  • Graham Capital Management's Castle Biosciences position peaked at $1.62M in Q2 2022.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.